The loss of MTAP has been identified as a potential therapeutic target in cancer due to its multiple cellular effects.7 10 24 In MTAP deficient cells, the accumulation of its substrate methylthioadenosine (MTA)24 can hamper the activity of protein arginine methyltransferase 5 (PRMT5) via direct feedback.10 Here, PRMT5 is linked to cancer.